User menu

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML, or AML with ⩽ 30% blasts.

Bibliographic reference Garcia-Manero, G ; Sekeres, M A ; Egyed, M ; Breccia, M ; Graux, Carlos ; et. al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML, or AML with ⩽ 30% blasts.. In: Leukemia, Vol. 31, no. 12, p. 2799-2806 (2017)
Permanent URL http://hdl.handle.net/2078.1/185417
  1. Garcia-Manero Guillermo, Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management : Myelodysplastic Syndromes: 2015 Update, 10.1002/ajh.24102
  2. Nimer S. D., Myelodysplastic syndromes, 10.1182/blood-2007-08-078139
  3. Fenaux Pierre, Mufti Ghulam J., Hellström-Lindberg Eva, Santini Valeria, Gattermann Norbert, Germing Ulrich, Sanz Guillermo, List Alan F., Gore Steven, Seymour John F., Dombret Hervé, Backstrom Jay, Zimmerman Linda, McKenzie David, Beach C.L., Silverman Lewis R., Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia, 10.1200/jco.2009.23.8329
  4. Dombret H., Seymour J. F., Butrym A., Wierzbowska A., Selleslag D., Jang J. H., Kumar R., Cavenagh J., Schuh A. C., Candoni A., Recher C., Sandhu I., Bernal del Castillo T., Al-Ali H. K., Martinelli G., Falantes J., Noppeney R., Stone R. M., Minden M. D., McIntyre H., Songer S., Lucy L. M., Beach C. L., Dohner H., International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, 10.1182/blood-2015-01-621664
  5. Pleyer Lisa, Burgstaller Sonja, Girschikofsky Michael, Linkesch Werner, Stauder Reinhard, Pfeilstocker Michael, Schreder Martin, Tinchon Christoph, Sliwa Thamer, Lang Alois, Sperr Wolfgang R., Krippl Peter, Geissler Dietmar, Voskova Daniela, Schlick Konstantin, Thaler Josef, Machherndl-Spandl Sigrid, Theiler Georg, Eckmüllner Otto, Greil Richard, Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group, 10.1007/s00277-014-2126-9
  6. Fenaux Pierre, Mufti Ghulam J, Hellstrom-Lindberg Eva, Santini Valeria, Finelli Carlo, Giagounidis Aristoteles, Schoch Robert, Gattermann Norbert, Sanz Guillermo, List Alan, Gore Steven D, Seymour John F, Bennett John M, Byrd John, Backstrom Jay, Zimmerman Linda, McKenzie David, Beach CL, Silverman Lewis R, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, 10.1016/s1470-2045(09)70003-8
  7. Maurillo Luca, Venditti Adriano, Spagnoli Alessandra, Gaidano Gianluca, Ferrero Dario, Oliva Esther, Lunghi Monia, D'Arco Alfonso M., Levis Alessandro, Pastore Domenico, Di Renzo Nicola, Santagostino Alberto, Pavone Vincenzo, Buccisano Francesco, Musto Pellegrino, Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program, 10.1002/cncr.26354
  8. Laubach J. P., Moreau P., San-Miguel J. F., Richardson P. G., Panobinostat for the Treatment of Multiple Myeloma, 10.1158/1078-0432.ccr-15-0530
  9. Atadja Peter, Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges, 10.1016/j.canlet.2009.02.019
  10. DeAngelo D J, Spencer A, Bhalla K N, Prince H M, Fischer T, Kindler T, Giles F J, Scott J W, Parker K, Liu A, Woo M, Atadja P, Mishra K K, Ottmann O G, Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies, 10.1038/leu.2013.38
  11. Khan Hina, Vale Cristina, Bhagat Tushar, Verma Amit, Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes, 10.1053/j.seminhematol.2013.01.001
  12. Issa Jean-Pierre, Epigenetic Changes in the Myelodysplastic Syndrome, 10.1016/j.hoc.2010.02.007
  13. Fiskus Warren, Buckley Kate, Rao Rekha, Mandawat Aditya, Yang Yonghua, Joshi Rajeshree, Wang Yongchao, Balusu Ramesh, Chen Jianguang, Koul Sanjay, Joshi Atul, Upadhyay Sunil, Atadja Peter, Atadja Peter, Bhalla Kapil N., Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells, 10.4161/cbt.8.10.8213
  14. Soriano A. O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W. G., Ouzounian S., Quezada A., Pierce S., Estey E. H., Issa J.-P. J., Kantarjian H. M., Garcia-Manero G., Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome, 10.1182/blood-2007-03-078576
  15. Garcia-Manero G., Kantarjian H. M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W. G., Ravandi F., Koller C., Xiao L., Faderl S., Estrov Z., Cortes J., O'Brien S., Estey E., Bueso-Ramos C., Fiorentino J., Jabbour E., Issa J.-P., Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia, 10.1182/blood-2006-03-009142
  16. Richardson Paul G, Laubach Jacob P, Lonial Sagar, Moreau Philippe, Yoon Sung-Soo, Hungria Vânia TM, Dimopoulos Meletios A, Beksac Meral, Alsina Melissa, San-Miguel Jesús F, Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma, 10.1586/14737140.2015.1047770
  17. Cheson Bruce D., Bennett John M., Kopecky Kenneth J., Büchner Thomas, Willman Cheryl L., Estey Elihu H., Schiffer Charles A., Doehner Hartmut, Tallman Martin S., Lister T. Andrew, Lo-Coco Francesco, Willemze Roel, Biondi Andrea, Hiddemann Wolfgang, Larson Richard A., Löwenberg Bob, Sanz Miguel A., Head David R., Ohno Ryuzo, Bloomfield Clara D., Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, 10.1200/jco.2003.04.036
  18. Cheson B. D., Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, 10.1182/blood-2005-10-4149
  19. Babb James, Rogatko André, Zacks Shelemyahu, Cancer phase I clinical trials: efficient dose escalation with overdose control, 10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9
  20. CLOPPER C. J., PEARSON E. S., THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL, 10.1093/biomet/26.4.404
  21. Prebet Thomas, Sun Zhuoxin, Figueroa Maria E., Ketterling Rhett, Melnick Ari, Greenberg Peter L., Herman James, Juckett Mark, Wang Eunice S., Smith Mitchell R., Malick Lisa, Paietta Elisabeth, Czader Magdalena, Litzow Mark, Gabrilove Janice, Erba Harry P., Gore Steven D., Tallman Martin S., Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905, 10.1200/jco.2013.50.3102
  22. Issa Jean-Pierre, Garcia-Manero Guillermo, Huang Xuelin, Cortes Jorge, Ravandi Farhad, Jabbour Elias, Borthakur Gautam, Brandt Mark, Pierce Sherry, Kantarjian Hagop M., Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia : Decitabine ± Valproic Acid in MDS-AML, 10.1002/cncr.29085
  23. Lübbert Michael, Kuendgen Andrea, Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges : Editorial, 10.1002/cncr.29083
  24. Blum William, Klisovic Rebecca B., Hackanson Bjoern, Liu Zhongfa, Liu Shujun, Devine Hollie, Vukosavljevic Tamara, Huynh Lenguyen, Lozanski Gerard, Kefauver Cheryl, Plass Christoph, Devine Steven M., Heerema Nyla A., Murgo Anthony, Chan Kenneth K., Grever Michael R., Byrd John C., Marcucci Guido, Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia, 10.1200/jco.2006.09.4169
  25. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu H B, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A, Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome, 10.1038/bcj.2013.68
  26. Zeidan Amer M., Davidoff Amy J., Long Jessica B., Hu Xin, Wang Rong, Ma Xiaomei, Gross Cary P., Abel Gregory A., Huntington Scott F., Podoltsev Nikolai A., Hajime Uno, Prebet Thomas, Gore Steven D., Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes, 10.1111/bjh.14305
  27. Fandy T. E., Herman J. G., Kerns P., Jiemjit A., Sugar E. A., Choi S.-H., Yang A. S., Aucott T., Dauses T., Odchimar-Reissig R., Licht J., McConnell M. J., Nasrallah C., Kim M. K. H., Zhang W., Sun Y., Murgo A., Espinoza-Delgado I., Oteiza K., Owoeye I., Silverman L. R., Gore S. D., Carraway H. E., Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies, 10.1182/blood-2009-02-203547
  28. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W. G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V. R., Randolph S. S., Hardwick J. S., Reilly J. F., Chen C., Ricker J. L., Secrist J. P., Richon V. M., Frankel S. R., Kantarjian H. M., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes, 10.1182/blood-2007-06-098061
  29. Kirschbaum Mark, Gojo Ivana, Goldberg Stuart L., Bredeson Christopher, Kujawski Lisa A., Yang Allen, Marks Peter, Frankel Paul, Sun Xing, Tosolini Alessandra, Eid Joseph E., Lubiniecki Gregory M., Issa Jean-Pierre, A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome, 10.1111/bjh.13016
  30. Lee Yun-Gyoo, Kim Inho, Yoon Sung-Soo, Park Seonyang, Cheong June Won, Min Yoo Hong, Lee Jeong-Ok, Bang Soo-Mee, Yi Hyeon Gyu, Kim Chul Soo, Park Yong, Kim Byung-Soo, Mun Yeung-Chul, Seong Chu-Myoung, Park Jinny, Lee Jae Hoon, Kim Sung-Yong, Lee Hong Ghi, Kim Yeo-Kyeoung, Kim Hyeoung-Joon, , Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes, 10.1111/bjh.12256
  31. Maslak P, Chanel S, Camacho L H, Soignet S, Pandolfi P P, Guernah I, Warrell R, Nimer S, Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome, 10.1038/sj.leu.2404050
  32. Gore Steven D., Baylin Stephen, Sugar Elizabeth, Carraway Hetty, Miller Carole B., Carducci Michael, Grever Michael, Galm Oliver, Dauses Tianna, Karp Judith E., Rudek Michelle A., Zhao Ming, Smith B. Douglas, Manning Jasper, Jiemjit Anchalee, Dover George, Mays Abbie, Zwiebel James, Murgo Anthony, Weng Li-Jun, Herman James G., Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms, 10.1158/0008-5472.can-06-0080
  33. Raffoux Emmanuel, Cras Audrey, Recher Christian, Boëlle Pierre-Yves, de Labarthe Adrienne, Turlure Pascal, Marolleau Jean-Pierre, Reman Oumedaly, Gardin Claude, Victor Maud, Maury Sébastien, Rousselot Philippe, Malfuson Jean-Valère, Maarek Odile, Daniel Marie-Thérèse, Fenaux Pierre, Degos Laurent, Chomienne Christine, Chevret Sylvie, Dombret Hervé, Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome, 10.18632/oncotarget.106
  34. Merkel Drorit, Filanovsky Kalman, Gafter-Gvili Anat, Vidal Liat, Aviv Ariel, Gatt Moshe E., Silbershatz Itay, Herishanu Yair, Arad Ariela, Tadmor Tamar, Dally Najib, Nemets Anatoly, Rouvio Ory, Ronson Aharon, Herzog-Tzarfati Katrin, Akria Luiza, Braester Andrei, Hellmann Ilana, Yeganeh Shay, Nagler Arnon, Leiba Ronit, Mittelman Moshe, Ofran Yishai, Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study, 10.1002/ajh.23368
  35. Ofran Yishai, Filanovsky Kalman, Gafter-Gvili Anat, Vidal Liat, Aviv Ariel, Gatt Moshe E., Silbershatz Itay, Herishanu Yair, Arad Ariela, Tadmor Tamar, Dally Najib, Nemets Anatoly, Rouvio Ory, Ronson Aharon, Herzog-Tzarfati Katrin, Akria Luiza, Braester Andrei, Hellmann Ilana, Yeganeh Shay, Nagler Arnon, Leiba Ronit, Mittelman Moshe, Merkel Drorit, Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome, 10.1016/j.clml.2015.02.030